quinuclidines has been researched along with Diseases, Metabolic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, C; Han, M; Lian, J; Su, Y | 1 |
1 other study(ies) available for quinuclidines and Diseases, Metabolic
| Article | Year |
|---|---|
Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.
Topics: AMP-Activated Protein Kinases; Animals; Antipsychotic Agents; Female; Liver; Metabolic Diseases; Muscarinic Agonists; Olanzapine; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M3; Signal Transduction; Thiophenes; Weight Gain | 2022 |